{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:53:58Z","timestamp":1791125638890,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,1,19]],"date-time":"2011-01-19T00:00:00Z","timestamp":1295395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>A prospective clinical trial was performed in order to validate the pharmacokinetic (PK) and clinical benefits of a new dosing schedule of intravenous busulfan (IV Bu) in children.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>IV Bu was administered as a 2\u2010hr infusion every 6\u2009hr for 4 days. Five dose levels were given according to body\u2010weight strata.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 67 children aged from 4 months to 17.2 years were followed up over 50 months after autologous or allogeneic stem\u2010cell transplantation. Reduced PK variability was seen after IV Bu administration enabling efficient targeting with 78% of patients within the 900\u20131,500\u2009\u00b5M\u2009\u00b7\u2009min therapeutic window and reproducible exposures across administrations. No neurological complications occurred. The low incidence of hepatic veno\u2010occlusive disease (VOD) recorded was not correlated with high area under the curve (AUC). Only stomatitis was correlated with high AUC in the autologous group. The 4\u2010year overall survival was 59% in the autologous group and 82% in the allogeneic group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The new dosing schedule using IV Bu provides adequate therapeutic targeting from the first administration, with low toxicity and good disease control in high\u2010risk children. The choice of this formulation of Bu should be considered because of its low morbidity and good outcome. Pediatr Blood Cancer 2012; 58: 90\u201397. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.22959","type":"journal-article","created":{"date-parts":[[2011,1,19]],"date-time":"2011-01-19T18:50:53Z","timestamp":1295463053000},"page":"90-97","source":"Crossref","is-referenced-by-count":51,"title":["Weight\u2010based strategy of dose administration in children using intravenous busulfan: Clinical and pharmacokinetic results"],"prefix":"10.1002","volume":"58","author":[{"given":"G\u00e9rard","family":"Michel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Valteau\u2010Couanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Claude","family":"Gentet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Esperou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Soci\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"M\u00e9chinaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Doz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Galambrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Demeocq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Yakouben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bordigoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Frappaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Vassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,19]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3669"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1217"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90477-0"},{"key":"e_1_2_6_5_2","first-page":"12","article-title":"The development of busulfan\/cyclophosphamide preparative regimens","volume":"20","author":"Santos GW","year":"1993","journal-title":"Semin Oncol"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198312013092202"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00688324"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood.V75.8.1723.1723","article-title":"Busulfan disposition in children","volume":"75","author":"Grochow LB","year":"1990","journal-title":"Blood"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.7.2144.2144"},{"key":"e_1_2_6_10_2","first-page":"843","article-title":"Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders","volume":"18","author":"Hassan M","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_11_2","first-page":"31","article-title":"Graft\u2010rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics","volume":"16","author":"Slattery JT","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.8.3055"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703207"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702371"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703612"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703264"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2002.v8.pm11939604"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2002.v8.pm12374452"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704461"},{"key":"e_1_2_6_20_2","first-page":"58","article-title":"The impact of switching from oral IV busulfan of haematopoietic stem cell transplantation","volume":"12","author":"Nguyen L","year":"2006","journal-title":"EJHP Practice"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0029-0"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0652-5"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704446"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0455-2"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-4-199302150-00003"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197410000-00001"},{"key":"e_1_2_6_27_2","unstructured":"EMA guideline ICH topic E6 guideline for good clinical practice. ICH Harmonised Tripartite Guideline 1996."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100168"},{"key":"e_1_2_6_29_2","first-page":"467","article-title":"Hepatic veno\u2010occlusive disease post\u2010bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: Incidence, risk factors, and clinical outcome","volume":"7","author":"Ozkaynak MF","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2002.v8.pm12374454"},{"key":"e_1_2_6_31_2","first-page":"1396","article-title":"A prospective survey on incidence, risk factors and therapy of hepatic veno\u2010occlusive disease in children after hematopoietic stem cell transplantation","volume":"90","author":"Cesaro S","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701506"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.186"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703047"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198712000-00011"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9592.2002.00616.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847040-00002"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.112"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704275"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702806"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)00227-X"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701737"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.8925"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.69"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702376"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200709040-00008"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.16"},{"key":"e_1_2_6_49_2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/blood.V110.11.617.617","article-title":"Impact of conditioning regimen in allogeneic hematopoietic stem cell transplantation for children with acute myeloid leukemia in first complete remission: Total\u2010body irradiation and cyclophosphamide versus busulfan and cyclophosphamide\u2014A report from The Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"110","author":"Dalle J","year":"2007","journal-title":"Blood"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-911X(20001001)35:4<403::AID-MPO2>3.0.CO;2-M"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-265405"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22959","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22959","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.22959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T10:56:50Z","timestamp":1696935410000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.22959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,19]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1002\/pbc.22959"],"URL":"https:\/\/doi.org\/10.1002\/pbc.22959","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,19]]}}}